CL2023001574A1 - Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas - Google Patents
Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicasInfo
- Publication number
- CL2023001574A1 CL2023001574A1 CL2023001574A CL2023001574A CL2023001574A1 CL 2023001574 A1 CL2023001574 A1 CL 2023001574A1 CL 2023001574 A CL2023001574 A CL 2023001574A CL 2023001574 A CL2023001574 A CL 2023001574A CL 2023001574 A1 CL2023001574 A1 CL 2023001574A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- diseases
- ophthalmological diseases
- sgc activators
- ophthalmological
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 2
- 201000007917 background diabetic retinopathy Diseases 0.000 abstract 2
- CANSPPZTVXEOJH-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxylic acid Chemical class C1CCNC2=C1NN=C2C(=O)O CANSPPZTVXEOJH-UHFFFAOYSA-N 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 108091008695 photoreceptors Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000003994 retinal ganglion cell Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a ácidos pirazolo piperidin carboxílicos sustituidos, sus sales y su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de enfermedades oftalmológicas, que incluyen retinopatía diabética no proliferativa (NPDR), edema macular diabético (DME), neurodegeneración de células ganglionares retinianas / fotorreceptores y cataratas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063123787P | 2020-12-10 | 2020-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001574A1 true CL2023001574A1 (es) | 2023-11-17 |
Family
ID=79185918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001574A CL2023001574A1 (es) | 2020-12-10 | 2023-06-01 | Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas |
Country Status (12)
Country | Link |
---|---|
US (2) | US20220241273A1 (es) |
EP (1) | EP4259140A1 (es) |
JP (2) | JP7458683B2 (es) |
KR (1) | KR20230118143A (es) |
CN (1) | CN115175681A (es) |
AU (1) | AU2021398486A1 (es) |
CA (1) | CA3204596A1 (es) |
CL (1) | CL2023001574A1 (es) |
IL (1) | IL303297A (es) |
MX (1) | MX2023006902A (es) |
TW (1) | TW202237105A (es) |
WO (1) | WO2022122917A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
KR20110013388A (ko) * | 2008-05-10 | 2011-02-09 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 청력 장애 치료용 sGC 자극제, sGC 활성화제 및 그의 조합물 |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
MA34019B1 (fr) | 2010-02-27 | 2013-02-01 | Bayer Ip Gmbh | Aryltriazolone liée à un bis-aryle et son utilisation |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
US8895583B2 (en) * | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
WO2012076466A2 (de) | 2010-12-07 | 2012-06-14 | Bayer Pharma Aktiengesellschaft | Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3,4-b]吡啶-4-羧酸酰胺衍生物 |
FR3008618A1 (fr) * | 2013-07-19 | 2015-01-23 | Univ Paris Curie | Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine |
WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
ES2697902T3 (es) | 2014-11-03 | 2019-01-29 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
CA3098475A1 (en) * | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
WO2020245342A1 (en) * | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2021
- 2021-12-09 EP EP21835679.8A patent/EP4259140A1/en active Pending
- 2021-12-09 MX MX2023006902A patent/MX2023006902A/es unknown
- 2021-12-09 CN CN202180015751.9A patent/CN115175681A/zh active Pending
- 2021-12-09 WO PCT/EP2021/084991 patent/WO2022122917A1/en active Application Filing
- 2021-12-09 KR KR1020237022817A patent/KR20230118143A/ko unknown
- 2021-12-09 JP JP2022537408A patent/JP7458683B2/ja active Active
- 2021-12-09 AU AU2021398486A patent/AU2021398486A1/en active Pending
- 2021-12-09 CA CA3204596A patent/CA3204596A1/en active Pending
- 2021-12-09 IL IL303297A patent/IL303297A/en unknown
- 2021-12-09 TW TW110146058A patent/TW202237105A/zh unknown
-
2022
- 2022-02-08 US US17/667,418 patent/US20220241273A1/en active Pending
-
2023
- 2023-04-14 US US18/134,875 patent/US20230346777A1/en active Pending
- 2023-06-01 CL CL2023001574A patent/CL2023001574A1/es unknown
-
2024
- 2024-03-15 JP JP2024041631A patent/JP2024073585A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024073585A (ja) | 2024-05-29 |
CN115175681A (zh) | 2022-10-11 |
US20220241273A1 (en) | 2022-08-04 |
AU2021398486A1 (en) | 2023-06-22 |
EP4259140A1 (en) | 2023-10-18 |
TW202237105A (zh) | 2022-10-01 |
MX2023006902A (es) | 2023-06-26 |
US20230346777A1 (en) | 2023-11-02 |
IL303297A (en) | 2023-07-01 |
JP2023514928A (ja) | 2023-04-12 |
AU2021398486A9 (en) | 2024-02-08 |
JP7458683B2 (ja) | 2024-04-01 |
KR20230118143A (ko) | 2023-08-10 |
CA3204596A1 (en) | 2022-06-16 |
WO2022122917A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
CO2020015228A2 (es) | Sales de un inhibidor de fgfr | |
CL2023001574A1 (es) | Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
GB2540638A8 (en) | Compositions, Formulations and methods for treating ocular diseases | |
NI202000083A (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
UY27878A1 (es) | Derivados de indolinfenilsulfonamida | |
AR065135A1 (es) | Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
UY31676A1 (es) | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
UY30587A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus | |
UY29065A1 (es) | Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos. | |
CO2022000659A2 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
CO6251249A2 (es) | Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer | |
CO6361926A2 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales | |
AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina | |
UY30582A1 (es) | Derivados de acido 2-fenoxinicotinico y su uso | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
UY30705A1 (es) | Sulfonamidas sustituidas |